| Issue Date | Title | Author(s) | Source | scopus | WOS | Fulltext/Archive link |
| 2012 | Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): A phase 2 trial | Yang J.C.H.; Shih J.-Y.; Su W.-C.; Hsia T.-C.; Tsai C.-M.; Ou S.H.I.; Yu C.-J.; Chang G.-C.; Ho C.-L.; Sequist L.V.; Dudek A.Z.; Shahidi M.; Cong X.J.; Lorence R.M.; PAN-CHYR YANG ; Miller V.A. | The Lancet Oncology | 348 | 316 | |
| 2012 | Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): A phase 2 trial | Yang J.C.H.; JIN-YUAN SHIH ; Su W.-C.; Hsia T.-C.; Tsai C.-M.; Ou S.H.I.; Yu C.-J.; Chang G.-C.; Ho C.-L.; Sequist L.V.; Dudek A.Z.; Shahidi M.; Cong X.J.; Lorence R.M.; Yang P.-C.; Miller V.A. | The Lancet Oncology | 321 | 316 | |
| 2012 | Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): A phase 2 trial | Yang J.C.H.; Shih J.-Y.; Su W.-C.; Hsia T.-C.; Tsai C.-M.; Ou S.H.I.; CHONG-JEN YU ; Chang G.-C.; Ho C.-L.; Sequist L.V.; Dudek A.Z.; Shahidi M.; Cong X.J.; Lorence R.M.; Yang P.-C.; Miller V.A. | The Lancet Oncology | | | |
| 2015 | Bulk intermixing-type perovskite CH3NH3PbI3/TiO2 nanorod hybrid solar cells | Li S.-S.; Wang Y.-C.; Tsai C.-M.; Wen C.-Y.; Yu C.-H.; Yang Y.-P.; Lin J.-C.; Wang D.-Y.; Chen C.-C.; Yeh Y.-C.; Chen C.-W.; CHUN-WEI CHEN | Nanoscale | 14 | 13 | |
| 2021 | Ceritinib Efficacy and Safety in Treatment-Naive Asian Patients With Advanced ALK-Rearranged NSCLC: An ASCEND-4 Subgroup Analysis | Tan D.S.W.; Geater S.; CHONG-JEN YU ; Tsai C.-M.; Hsia T.-C.; Chen J.; Lin M.-C.; Lu Y.; Sriuranpong V.; Yang C.-T.; Sen P.; Branle F.; Shi M.; Wu Y.-L. | JTO Clinical and Research Reports | | | |
| 2016 | Characteristics of young lung cancer: Analysis of Taiwan's nationwide lung cancer registry focusing on epidermal growth factor receptor mutation and smoking status | Hsu C.-H.; Tseng C.-H.; Chiang C.-J.; Hsu K.-H.; Tseng J.-S.; Chen K.-C.; Wang C.-L.; Chen C.-Y.; Yen S.-H.; Chiu C.-H.; Huang M.-S.; Yu C.-J.; Tsai Y.-H.; Chen J.-S.; Tsai C.-M.; Chou T.-Y.; Lin K.-C.; Tsai M.-H.; WEN-CHUNG LEE ; Ku H.-Y.; Liu T.-W.; Yang T.-Y.; Chang G.-C. | Oncotarget | 29 | 23 | |
| 2016 | Characteristics of young lung cancer: Analysis of Taiwan's nationwide lung cancer registry focusing on epidermal growth factor receptor mutation and smoking status | Hsu C.-H.; Tseng C.-H.; Chiang C.-J.; Hsu K.-H.; Tseng J.-S.; Chen K.-C.; Wang C.-L.; Chen C.-Y.; Yen S.-H.; Chiu C.-H.; Huang M.-S.; Yu C.-J.; Tsai Y.-H.; JIN-SHING CHEN ; Tsai C.-M.; Chou T.-Y.; Lin K.-C.; Tsai M.-H.; Lee W.-C.; Ku H.-Y.; Liu T.-W.; Yang T.-Y.; Chang G.-C. | Oncotarget | 22 | 23 | |
| 2016 | Characteristics of young lung cancer: Analysis of Taiwan's nationwide lung cancer registry focusing on epidermal growth factor receptor mutation and smoking status | Hsu C.-H.; Tseng C.-H.; CHUN-JU CHIANG ; Hsu K.-H.; Tseng J.-S.; Chen K.-C.; Wang C.-L.; Chen C.-Y.; Yen S.-H.; Chiu C.-H.; Huang M.-S.; Yu C.-J.; Tsai Y.-H.; Chen J.-S.; Tsai C.-M.; Chou T.-Y.; Lin K.-C.; Tsai M.-H.; Lee W.-C.; Ku H.-Y.; Liu T.-W.; Yang T.-Y.; Chang G.-C. | Oncotarget | | 23 | |
| 2016 | Characteristics of young lung cancer: Analysis of Taiwan's nationwide lung cancer registry focusing on epidermal growth factor receptor mutation and smoking status | Hsu C.-H.; Tseng C.-H.; Chiang C.-J.; Hsu K.-H.; Tseng J.-S.; Chen K.-C.; Wang C.-L.; Chen C.-Y.; Yen S.-H.; Chiu C.-H.; Huang M.-S.; CHONG-JEN YU ; Tsai Y.-H.; Chen J.-S.; Tsai C.-M.; Chou T.-Y.; Lin K.-C.; Tsai M.-H.; Lee W.-C.; Ku H.-Y.; Liu T.-W.; Yang T.-Y.; Chang G.-C. | Oncotarget | | | |
| 2015 | Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: A combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6 | Yang J.C.-H.; Sequist L.V.; Geater S.L.; Tsai C.-M.; Mok T.S.K.; Schuler M.; Yamamoto N.; CHONG-JEN YU ; Ou S.H.I.; Zhou C.; Massey D.; Zazulina V.; Wu Y.-L. | The Lancet Oncology | | | |
| 2011 | Different efficacies of erlotinib and gefitinib in Taiwanese patients with advanced non-small cell lung cancer: A retrospective multicenter study | Fan W.-C.; CHONG-JEN YU ; Tsai C.-M.; Huang M.-S.; Lai C.-L.; Hsia T.-C.; Tien Y.-J.; Huang S.-F.; Wu C.-H.; Chou K.-T.; Lee Y.-C.; Perng R.-P.; Chen Y.-M. | Journal of Thoracic Oncology | | | |
| 2017 | EGFR mutation, smoking, and gender in advanced lung adenocarcinoma | Tseng C.-H.; CHUN-JU CHIANG ; Tseng J.-S.; Yang T.-Y.; Hsu K.-H.; Chen K.-C.; Wang C.-L.; Chen C.-Y.; Yen S.H.; Tsai C.-M.; Huang M.-S.; Ho C.-C.; Yu C.-J.; Tsai Y.-H.; Chen J.-S.; Chou T.-Y.; Tsai M.-H.; Chen H.-Y.; Su K.-Y.; Chen J.J.W.; Chen H.-W.; Yu S.-L.; Liu T.-W.; Chang G.-C. | Oncotarget | | 0 | |
| 2017 | EGFR mutation, smoking, and gender in advanced lung adenocarcinoma | Tseng C.-H.; Chiang C.-J.; Tseng J.-S.; Yang T.-Y.; Hsu K.-H.; Chen K.-C.; Wang C.-L.; Chen C.-Y.; Yen S.H.; Tsai C.-M.; Huang M.-S.; Ho C.-C.; Yu C.-J.; Tsai Y.-H.; Chen J.-S.; Chou T.-Y.; Tsai M.-H.; Chen H.-Y.; Su K.-Y.; Chen J.J.W.; HUEI-WEN CHEN ; Yu S.-L.; Liu T.-W.; Chang G.-C. | Oncotarget | | 0 | |
| 2017 | EGFR mutation, smoking, and gender in advanced lung adenocarcinoma | Tseng C.-H.; Chiang C.-J.; Tseng J.-S.; Yang T.-Y.; Hsu K.-H.; Chen K.-C.; Wang C.-L.; Chen C.-Y.; Yen S.H.; Tsai C.-M.; Huang M.-S.; Ho C.-C.; Yu C.-J.; Tsai Y.-H.; JIN-SHING CHEN ; Chou T.-Y.; Tsai M.-H.; Chen H.-Y.; Su K.-Y.; Chen J.J.W.; Chen H.-W.; Yu S.-L.; Liu T.-W.; Chang G.-C. | Oncotarget | 23 | 0 | |
| 2017 | EGFR mutation, smoking, and gender in advanced lung adenocarcinoma | Tseng C.-H.; Chiang C.-J.; Tseng J.-S.; Yang T.-Y.; Hsu K.-H.; Chen K.-C.; Wang C.-L.; Chen C.-Y.; Yen S.H.; Tsai C.-M.; Huang M.-S.; Ho C.-C.; Yu C.-J.; Tsai Y.-H.; Chen J.-S.; Chou T.-Y.; Tsai M.-H.; Chen H.-Y.; Su K.-Y.; Chen J.J.W.; Chen H.-W.; SUNG-LIANG YU ; Liu T.-W.; Chang G.-C. | Oncotarget | 23 | 0 | |
| 2017 | EGFR mutation, smoking, and gender in advanced lung adenocarcinoma | Tseng C.-H.; Chiang C.-J.; Tseng J.-S.; Yang T.-Y.; Hsu K.-H.; Chen K.-C.; Wang C.-L.; Chen C.-Y.; Yen S.H.; Tsai C.-M.; Huang M.-S.; Ho C.-C.; Yu C.-J.; Tsai Y.-H.; Chen J.-S.; Chou T.-Y.; Tsai M.-H.; Chen H.-Y.; KANG-YI SU ; Chen J.J.W.; Chen H.-W.; Yu S.-L.; Liu T.-W.; Chang G.-C. | Oncotarget | 23 | 0 | |
| 2017 | EGFR mutation, smoking, and gender in advanced lung adenocarcinoma | Tseng C.-H.; Chiang C.-J.; Tseng J.-S.; Yang T.-Y.; Hsu K.-H.; Chen K.-C.; Wang C.-L.; Chen C.-Y.; Yen S.H.; Tsai C.-M.; Huang M.-S.; CHAO-CHI HO ; Yu C.-J.; Tsai Y.-H.; Chen J.-S.; Chou T.-Y.; Tsai M.-H.; Chen H.-Y.; Su K.-Y.; Chen J.J.W.; Chen H.-W.; Yu S.-L.; Liu T.-W.; Chang G.-C. | Oncotarget | 23 | 0 | |
| 2017 | EGFR mutation, smoking, and gender in advanced lung adenocarcinoma | Tseng C.-H.; Chiang C.-J.; Tseng J.-S.; Yang T.-Y.; Hsu K.-H.; Chen K.-C.; Wang C.-L.; Chen C.-Y.; Yen S.H.; Tsai C.-M.; Huang M.-S.; CHAO-CHI HO; Yu C.-J.; Tsai Y.-H.; Chen J.-S.; Chou T.-Y.; Tsai M.-H.; Chen H.-Y.; Su K.-Y.; Chen J.J.W.; Chen H.-W.; Yu S.-L.; Liu T.-W.; Chang G.-C. | Oncotarget | 23 | 0 | |
| 2017 | EGFR mutation, smoking, and gender in advanced lung adenocarcinoma | Tseng C.-H.; Chiang C.-J.; Tseng J.-S.; Yang T.-Y.; Hsu K.-H.; Chen K.-C.; Wang C.-L.; Chen C.-Y.; Yen S.H.; Tsai C.-M.; Huang M.-S.; Ho C.-C.; CHONG-JEN YU ; Tsai Y.-H.; Chen J.-S.; Chou T.-Y.; Tsai M.-H.; Chen H.-Y.; Su K.-Y.; Chen J.J.W.; Chen H.-W.; Yu S.-L.; Liu T.-W.; Chang G.-C. | Oncotarget | | | |
| 2015 | Epidermal growth factor receptor tyrosine Kinase inhibitor treatment response in advanced lung adenocarcinomas with G719X/L861Q/S768I mutations | Chiu C.-H.; Yang C.-T.; JIN-YUAN SHIH ; Huang M.-S.; Su W.-C.; Lai R.-S.; Wang C.-C.; Hsiao S.-H.; Lin Y.-C.; Ho C.-L.; Hsia T.-C.; Wu M.-F.; Lai C.-L.; Lee K.-Y.; Lin C.-B.; Yu-Wung Yeh D.; Chuang C.-Y.; Chang F.-K.; Tsai C.-M.; Perng R.-P.; Chih-Hsin Yang J. | Journal of Thoracic Oncology | 102 | 133 | |
